- Home
- MNOV vs AVTX Comparison
MNOV vs AVTX Comparison
Compare MNOV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | AVTX |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 248.3M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNOV | AVTX |
|---|---|---|
| Price | $1.86 | $15.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $7.00 | ★ $32.29 |
| AVG Volume (30 Days) | 102.0K | ★ 261.7K |
| Earning Date | 02-18-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $257,917.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $3.39 |
| 52 Week High | $2.06 | $20.72 |
Technical Indicators
Market Signals| Indicator | MNOV | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 75.07 | 44.21 |
| Support Level | $1.55 | $15.37 |
| Resistance Level | $1.92 | $17.12 |
| Average True Range (ATR) | 0.08 | 1.11 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 89.28 | 41.59 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).